الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 156 |  |  |
| | | from | 156 | | |
Abstract
Background:
The most frequent form of primary liver cancer is hepatocellular carcinoma (HCC). These tumours are typically only discovered after they are already advanced. There is a pressing need for new, efficient treatments because there are no viable treatments for people with advanced stage HCC.
Aim of work:
The study’s objective is to assess the safety and efficacy of peripheral blood derived autologous dendritic cells (DCs) vaccine in decreasing region of tumor and the overall prognosis of advanced HCC patients in comparison to supportive therapy in Egypt.
Materials and Methods:
This studywas carried out at tropical medicine and gastroenterology department – faculty of medicine - Sohag university in duration between April 2018 and March 2019, including 36 patients (29 males and 7 females), was subdivided into; group (I): which included 19 patients (14 males and 5 females) with Hepatocellular carcinoma (HCC) took supportive treatment, group (II): which included 17 patients (15 males and 2 females) with Hepatocellular carcinoma (HCC) were injected with DCs vaccine.
Results:
All of the markers changed significantly after injection. This led to significant difference between injection group after injection and control group regarding CD4+ % and CD4-CD8-%, and highly significant differences regarding CD4+ CD8+ %, CD16+ % and CD56+ %.
Conclusion:
DCs significantly reduced the proportion of indicators and several particular clinical indexes which improved, including Alpha FetoProtein (AFP), Alanine Transaminase (ALT), Creatinine, Albumin and Complete Blood Count (CBC) parameters. The DC vaccine treatment may helppeople with invasive malignancies to maintain or even improve their quality of life.
Keywords: HepatoCellular Carcinoma, Dendritic Cell, Immunotherapy.